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A B S T R A C T
Systemic chemotherapy is a primary strategy in the treatment of cancer, but comes with a number of limitations
such as toxicity and unfavorable biodistribution. To overcome these issues, numerous targeting systems for
speciﬁc delivery of chemotherapeutics to tumor cells have been designed and evaluated. Such strategies gen-
erally address subsets of tumor cells, still allowing the progressive growth of tumor cells not expressing the
target. Moreover, tumor stem cells and tumor supportive cells, such as cancer associated ﬁbroblasts and cancer
associated macrophages, are left unaﬀected by this approach. In this review, we discuss an alternative targeting
strategy aimed at delivery of anti-tumor drugs to the tumoral extracellular matrix with the potential to eliminate
all cell types. The extracellular matrix of tumors is vastly diﬀerent from that of healthy tissue and oﬀers hooks for
targeted drug delivery. It is concluded that matrix targeting is promising, but that clinical studies are required to
evaluate translation.
1. Introduction
Targeted drug delivery of chemotherapeutics is an increasingly
important area in the ﬁeld of cancer treatment research. Although
conventional chemotherapy remains one of the most important treat-
ment modalities, signiﬁcant side eﬀects may be induced that can result
in preliminary cease of chemotherapy [1–3]. Moreover, chemother-
apeutics have an unfavorable biodistribution and are generally rapidly
removed from the body. Advanced drug delivery systems may over-
come these hurdles. By entrapping chemotherapeutics in a drug de-
livery system, exposure to healthy cells may be decreased, which, to-
gether with an increased concentration of chemotherapeutics
speciﬁcally at the tumor site, can result in enhanced treatment eﬃcacy
with reduced side eﬀects [4]. However, to achieve this, drug delivery
systems should be designed to deliver chemotherapeutics to tumors
only and not to surrounding healthy tissue. Several approaches, in-
cluding passive targeting and ligand mediated targeting, are currently
being evaluated to achieve local delivery to tumor cells. While the
majority of the ﬁeld is focusing on targeting the tumor cells itself, we
here discuss an alternative approach i.e. targeting the tumor's extra-
cellular matrix (ECM). This strategy may result in a higher treatment
eﬃcacy by aﬀecting not only tumor cells, but also tumor supportive
cells. Tumor supportive cells are considered to have major roles in
supporting tumor growth. The cancer associated ﬁbroblast (CAF), for
instance, is a tumor-distinctive cell type responsible for excretion of
proliferating, pro-angiogenic, and anti-immunogenic factors, creating
an ideal environment for tumor growth and subsequent metastasis [5].
Further, the cancer associated macrophage shares many of the tumor
supportive characteristics of CAFs. Once derived from monocytes to its
speciﬁc subtype and located in the ECM of tumors the cancer associated
macrophage is thought to produce and secrete tumor enhancing factors
[6,7]. Endothelial cells are another cell type considered as key players
in tumor growth. By facilitating the supply of nutrients (e.g. oxygen,
glucose, etc.) through the generation and support of novel blood vessels,
tumors continue to proliferate [8]. Finally, the tumor stem cell is a
major player in tumor progression. Tumor stem cells are considered
responsible for self-renewal of tumor cells thereby driving tumor
growth [9,10]. A strategy that simultaneously aﬀects tumor cells and
tumor supportive cells may be beneﬁcial in improving treatment eﬃ-
cacies. We will present an overview of the possibilities and limitations
of strategies to deliver chemotherapeutics to and release them in the
tumor extracellular matrix.
2. Conventional tumor targeting strategies
Passive targeting is one of the main strategies to guide drug delivery
systems to cancer cells making use of the enhanced permeability and
retention eﬀect (EPR) [11]. This phenomenon is based on newly formed
leaky vessels in tumor areas (permeability) with decreased lymphatic
drainage resulting in an increased retention [12]. As a result, accu-
mulation of drug delivery systems at the tumor site may occur. Despite
extensive evaluation over the last 30 years and initial promising
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preclinical results of passively targeted chemotherapeutic drug delivery
through the EPR eﬀect, serious questions have been raised about the
existence and clinical application of the EPR eﬀect in humans [13,14].
The opposite of passive targeting, active targeting, is therefore
under growing attention. Active targeting is based on the concept that
drug delivery systems can actively bind and subsequently internalize
into tumor cells using tumor cell speciﬁc antibodies or ligands [11,15].
The ideal target is highly overexpressed on tumor cells, and absent or
expressed to a limited extent on healthy cells. Examples are membrane
bound receptors such as the human epidermal growth factor receptor 2
(HER2), epidermal growth factor receptor-1 (EGFR), transferrin re-
ceptor and folate receptor-α. However, there are several limitations
associated with targeted delivery to tumors that need to be resolved in
order to further improve the treatment outcome.
3. Limitations of current targeting strategies
Conventional drug delivery systems that target tumor cells through
binding membrane bound molecules have several pitfalls. First, tumors
show a high intratumoral heterogeneity resulting in heterogeneous
expression of targets for drug delivery [16]. This may implicate that in
practice targeted therapy may result in removal of only the subset of
tumor cells expressing the target, while tumor cells lacking the target
are left unaﬀected. As a result, these cells may proceed proliferating and
ﬁnally result in a tumor lacking expression of the initial target (Fig. 1).
A second aspect of the current tumor targeting is the disregard of
tumor supportive cells being present in the tumoral extracellular matrix
(ECM). Tumor supportive cells are responsible for important cues for
tumor proliferation and involved in the maintenance of a tumor sup-
portive environment. Drug delivery strategies aimed at a speciﬁc tumor
cell can leave other tumor cells and, perhaps even more importantly,
tumor stem cells, tumor supportive cells and their supportive environ-
ment intact and may therefore not be suﬃcient to eradicate the whole
tumor and prevent relapse.
Thirdly, delivery of entrapped drugs to their location of action by a
targeted drug delivery system has proven more complex than initially
anticipated. The majority of the current targeting drug delivery systems
are designed to deliver their payload to their site of action (e.g. the
nucleus). For most chemotherapeutics, this implicates that once a drug
delivery system is bound to its target (e.g. membrane receptor) rapid
internalization should occur. Thereafter, the drug should be released
and subsequently move to its site of action, and not diﬀuse back into
circulation. Although targeting the tumor cell membrane with sub-
sequent internalization can be accomplished using antibodies or li-
gands, the steps to deliver chemotherapeutics to its site of action are
more complicated. Once internalized into lysosomal compartments in
the cytoplasm, the drug should be released from its carrier. A wide
range of drug delivery systems struggle to release their payload after
internalization because of failure to escape from lysosomal compart-
ments in which they end up after internalization [17,18]. For example,
the majority of injected PEGylated liposomal doxorubicin, a clinically
approved passive targeting drug delivery system for doxorubicin, is
found to be entrapped in lysosomes after internalization. In vivo ex-
periments have shown that as a consequence of this lysosomal entrap-
ment, less than 1% of the administered doxorubicin from liposomes
reaches the nucleus, its actual target [19]. Lysosomal sequestering of
drug delivery systems following internalization can thus prevent che-
motherapeutics from reaching their site of action.
Overall, the majority of the tumor targeting drug delivery strategies
for chemotherapeutic delivery focus on targeting tumor cells and may
result in eradication of only a speciﬁc subset of tumor cells.
Importantly, tumor supportive cells and tumor stem cells are left un-
aﬀected. Impaired release of chemotherapeutics and lysosomal en-
trapment may further limit the treatment eﬃcacy. Therefore, an al-
ternative targeting strategy that tackles these issues is desired.
4. Alternative tumor targeting strategy
Targeting chemotherapeutics to the extracellular matrix (ECM) of
tumors may be a promising alternative strategy that can oﬀer ad-
vantages over conventional targeting. The strategy is not aimed to
target membrane bound receptors on speciﬁc tumor cells, but is aimed
to target the unique tumoral ECM. Upon binding, depots of che-
motherapeutic carriers in the tumor ECM are formed. Finally, when
chemotherapeutics are released in the ECM they are able to diﬀuse to
and aﬀect all surrounding tumor cells including the heterogeneous
tumor cell subsets, tumor supportive cells and tumor stem cells (Fig. 2).
Here we will discuss this emerging ﬁeld and deﬁne a number of con-
ditions necessary to use drug delivery systems or antibody-drug con-
jugates as local extracellular chemotherapeutic depots.
4.1. The unique tumoral extracellular matrix
The normal ECM has many important functions including support
Fig. 1. Limitations of the conventional tumor targeting strategy. By addressing a speciﬁc tumor marker, tumor cells lacking the marker may survive and continue to grow progressively.
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and strength for tissues. It consists of various components such as
(glyco)proteins (e.g. tenascin, collagen, elastin, laminin, ﬁbronectin,
and proteoglycans) and glycosaminoglycans (e.g. heparan sulfate and
chondroitin sulfate) [21,22]. The tumoral ECM is considered distinct
from normal tissue ECM in various aspects. For instance, several types
of collagen are abundantly deposited during tumor formation and
chondroitin sulfate and heparan sulfate are also more abundantly pre-
sent in the ECM of tumors, both having the capacity to bind tumor
promoting growth factors. Moreover, ECM remodeling enzymes are
overexpressed in tumors [23]. It is believed that these factors contribute
to tumor progression and invasion. Consequently, the deregulated tu-
moral ECM may also provide targeting possibilities as the tumor ECM
may be enriched in certain molecules that are almost absent in normal
ECM.
4.2. Targets in the tumoral extracellular matrix
As mentioned, the tumoral ECM is distinct from the normal ECM
and may oﬀer targeting possibilities. To ensure speciﬁc tumor delivery,
the target should be expressed speciﬁcally in the ECM of tumors.
Several ECM targets that may be used for drug delivery have been
described as suitable. An overview of tumor ECM targeting strategies is
presented in Table 1, and some examples will be discussed here.
Tenascin-C is a large glycoprotein of about 300 kDa which is highly
expressed in the ECM of several tumors including breast, colon, lung,
and ovarian tumors. It supports several aspects of tumor growth, such
as tumor proliferation, angiogenesis and metastasis [24]. Moreover, its
expression in normal ECM is almost absent [24], making it suitable for
ECM targeting. Dal Corso et al. used a non-internalizing antibody di-
rected against tenascin-C to deliver a chemotherapeutic compound (the
anthracycline PNU159682) to the ECM of tumors [25]. Upon in-
travenous injection, the antibody-drug conjugate bound to tenascin-C
(Fig. 3) and the drug was released through cleavage of the protease-
sensitive linker between the drug and antibody. Signiﬁcant tumor
growth inhibition was observed in epidermoid carcinoma mouse xe-
nografts. Chen et al. developed a strategy targeting tenascin-C using
liposomes functionalized with a tenascin-C binding peptide and loaded
with navitoclax, a small molecule inducing apoptosis primarily in CAFs.
These liposomes modulated the ECM of tumors through eﬃcient re-
moval of CAFs, making the ECM more accessible for subsequently ad-
ministered doxorubicin loaded nanoparticles [26,27]. Because only
CAFs were aﬀected by the initial ECM targeting strategy, they still had
to apply a subsequent tumor cell speciﬁc targeting method. Using na-
noparticles containing doxorubicin and targeting the human transferrin
receptor, signiﬁcant tumor growth inhibition was observed in liver
tumor-bearing mice. Kang et al. targeted both, tumor cells using neu-
ropilin-1 and tumor ECM tenascin-C with nanoparticles for glioma
therapy. When loaded with paclitaxel, they tripled the median survival
of intracranial glioma tumor bearing mice [28]. Lin et al. evaluated
another tenascin-C targeting strategy. Doxorubicin loaded liposomes
functionalized with sulfatide, a tenascin-C binding glycosphingolipid,
were evaluated in mice bearing subcutaneous colorectal tumors and
subcutaneous glioma tumors [29–32]. Although prolonged survival and
decreased side eﬀects were observed, the strategy was still dependent
on endocytic cellular uptake of liposomes by glioma cells, which may
limit the full potential of this strategy due to lysosomal entrapment of
the liposomes. Another tenascin-C targeting approach was evaluated by
Li et al. in a breast cancer mouse model. Mice were treated with pa-
clitaxel loaded sulfatide-containing lipid nanoparticles. Again, despite
increased eﬃcacy over non-targeted delivery and free drug, the
Fig. 2. A schematic overview of targeting to the extracellular matrix. Drug delivery systems bind to a molecule abundantly present in the extracellular matrix of tumors. Upon binding, the
chemotherapeutic compound is released and diﬀuses into all tumor cell subsets, but also into other cells (e.g. cancer associated ﬁbroblasts, cancer associated macrophages, tumor stem
cells). Adapted from Van der Steen et al. [20] under the Creative Commons Attribution License (CC BY 4.0).
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nanoparticles had to internalize into tumor cells in order to function
[33]. It should be noted, however, that sulfatide, while suitable for
incorporation in lipid based drug delivery particles (e.g. liposomes) and
favoring binding to tenascin-C, has been reported to bind other matrix
molecules [32], which could result in potential oﬀ-target eﬀects.
Therefore, the use of a tenascin-C binding peptide or a selected aptamer
[34,35] may be preferred. Overall, tenascin-C appears to be a promising
target because of its almost exclusive expression in the ECM of tumors.
However, most tenascin-C targeting strategies could be improved by
introducing drug release in the ECM to overcome potential lysosomal
sequestration of the internalized drug delivery particles.
Another molecule to target in the ECM of tumors is ﬁbronectin, a
glycoprotein consisting of two 250 kDa subunits. Two alternatively
spliced isoforms (i.e. extra domain-A and -B) of ﬁbronectin are abun-
dantly present in the tumor ECM of various types of cancer and almost
absent in the normal ECM, making them prospective targets for ECM
drug delivery (as extensively reviewed in [36,37]). A few studies
evaluated ﬁbronectin as a target for ECM targeted cancer treatment. For
instance, Perrino et al. showed that a straightforward strategy, tar-
geting the ﬁbronectin extra domain-A with an antibody-drug (may-
tansinoid derivative MD1) conjugate, was able to induce complete re-
mission in a subcutaneous teratocarcinoma mouse model [38].
Interestingly, this approach was based on non-internalizing antibodies
that released the drug extracellularly due to the release of reducing
agents (e.g. cysteine or glutathione) from dying cells which then re-
leased the drug by reduction of the disulﬁde bonds. These results sug-
gest that release of a chemotherapeutic drug in the ECM of tumors can
indeed aﬀect the whole tumor. Additionally, it was shown by Park et al.
that nanoparticles functionalized with peptides with a high aﬃnity
towards ﬁbronectin extra domain B accumulated speciﬁcally in tumors
of a Lewis lung carcinoma model [39]. Alternatively, other groups used
a combination of liposomes with single chain variable fragment (scFv)
antibodies against ﬁbronectin extra domain B for ECM targeting.
However, therapeutic in vivo studies in mice bearing subcutaneous
teratocarcinomas treated with ﬁbronectin extra domain B targeting li-
posomes loaded with the cytotoxic compound 5-FdU-NOAC showed no
signiﬁcant diﬀerences in comparison to non-targeting liposomes [40].
This lack of therapeutic advantage may be due to the absence of an
extracellular release mechanism resulting in the required internaliza-
tion of liposomes for therapeutic activity. Carnemolla et al. were able to
successfully target the ﬁbronectin extra domain B using a biologically
active fusion protein of interleukin-2 and a scFv antibody (clone L19) to
induce an anti-tumor immune response [41]. Subcutaneous F9-mouse
teratocarcinoma tumors were signiﬁcantly smaller when treated with
the interleukin-2-scFv conjugate, indicating that the L19 scFv may be a
suitable candidate to use for tumoral ECM drug delivery.
Others have targeted ﬁbronectin in the tumor ECM through its in-
teraction with plasma proteins. Plasma proteins extravasating through
vessels can form complexes with ﬁbronectin such as ﬁbrin-ﬁbronectin
[42]. This tumor speciﬁc complex, also called clotted plasma proteins,
may be used as a target to deliver chemotherapeutics to the tumor ECM.
In a glioblastoma mouse model, nanoparticles functionalized with CLT-
1 (CGLIIQKNEC), a ﬁbrin-ﬁbronectin binding peptide, loaded with
paclitaxel, were able to signiﬁcantly prolong survival. However, a
possible by-stander eﬀect by eliminating surrounding tumor (suppor-
tive) cells may have been limited because the strategy was dependent
on integrin mediated cellular internalization into tumor cells and not on
extracellular drug release [43]. Fibrin-ﬁbronectin targeting with the
CLT-1 peptide was also used by Tan et al. to visualize prostate tumors
by MRI indicating the suitability of CLT-1 for tumor ECM targeting
Table 1
Overview of drug delivery strategies targeting the extracellular matrix in tumors.
Target Targeting system Payload Remarks References
Tenascin-C Antibody drug conjugate Anthracycline
PNU159682
ECM release [25]
FHKHKSPALSPVGGG peptide-liposomesa Navitoclax Removal of CAFs, subsequent tumor cell
targeting of liposomes required
[26,27]
FHKHKSPALSPV peptide- tLyp-1-peptide nanoparticlesa Paclitaxel [28]
Sulfatide-liposomesa Doxorubicin [29–32]
Sulfatide-nanoparticlesa Paclitaxel [33]
Fibronectin extra domain
A or B
Antibody (SIP-F8) drug conjugate (extra domain A) Maytansinoid derivative
MD1
Extracellular release strategy [38]
Aptide-nanoparticles (extra domain B) Iron oxide Imaging only [39]
Single chain variable fragment (CGS-1)-liposomesa (extra domain
B)
5-FdU-NOAC [40]
Single chain variable fragment (L19)-interleukin 2 fusion protein
(extra domain B)
Interleukin 2 Stimulation of immune response [41]
Fibronectin-ﬁbrin
complex
CLT-1 peptide-FITC conjugation FITC Imaging only [42]
CLT-1 peptide-nanoparticlesa Paclitaxel [43]
CLT-1 imaging complex Gadolinium Imaging only [44,45]
CREKA-nanoparticles Iron oxide In vitro targeting [46]
CREKA-thermosensitive-liposomes Doxorubicin ECM release by external heat [47]
Antibody-drug conjugate SN-38 ECM release [48]
Collagen Antibody-drug conjugate to type IV collagen SN-38 ECM release [49]
Collagen-binding domain peptide fused with Fab fragment of an
antibody against EGFR (type of collagen not speciﬁed)
None Membrane receptor binding of speciﬁc
tumor cell subset required
[50]
Galectin-1 Anginex galectin-1 binding peptide-liposomesa Cisplatin and arsenic
trioxide
[51,52]
Aggrecan Quaternary ammonium-drug-conjugate Melphalan Therapeutic mechanism not clear [53–55]
Heparan sulfate CGKRK peptide nanoparticles Paclitaxel Dual targeting to heparan sulfate and
endothelial cells
[57]
Chondroitin sulfate TRX-20 modiﬁed liposomesa Cisplatin [59]
Single chain variable fragment (GD3G7)-lyophilisomes (against CS
type E)
Doxorubicin ECM release, in vitro study [20]
a Internalization of carrier+drug required for therapeutic activity, endosomal escape necessary.
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[44,45]. Next, Kruse and co-workers used CREKA, a peptide that also
binds ﬁbrin-ﬁbronectin complexes [46]. Although the iron oxide na-
noparticles were able to speciﬁcally target ﬁbrin-ﬁbronectin in vitro, no
in vivo tumor targeting or therapeutic studies were reported. CREKA
was also used for tumoral ECM targeting by others. Wang et al. pre-
pared doxorubicin loaded CREKA-functionalized liposomes with ther-
mosensitive release characteristics. Mice bearing subcutaneous multi-
drug resistance adenocarcinomas showed signiﬁcant inhibition in
tumor growth when treated with doxorubicin loaded CREKA liposomes
[47]. Moreover, when tumors were heated to induce doxorubicin re-
lease, tumor growth was even more inhibited, indicating that upon
binding in the ECM of tumors, the released doxorubicin was able to
reach its site-of-action and aﬀected tumor growth. In a slightly diﬀerent
approach, Yasunage et al. targeted ﬁbrin clots in the tumoral ECM using
an antibody that was conjugated with the cytotoxic compound SN-38,
the active metabolite of irinotecan, that was modiﬁed to be only cy-
totoxic upon release from the antibody due to an alkaline labile ester
bond [48]. An in vivo therapeutic study in a chemically induced skin
carcinoma mouse model showed a signiﬁcant tumor growth inhibition
in mice treated with the antibody-drug conjugate. Further analyses
showed a signiﬁcantly higher concentration of the drug in tumors of
mice treated with the antibody drug conjugate, indicating that ﬁbrin-
ﬁbronectin targeting in the tumor ECM may be useful for targeted
chemotherapeutic drug delivery.
Although targeted less frequently, collagen may also be a potential
target in the ECM of tumors. Collagen is a structural protein abundantly
present in the ECM of most tissues. Despite the presence of collagen
throughout the body and risk of oﬀ-targeting with toxicity as a result,
several attempts have been made to target collagen in the tumoral ECM
for the delivery of chemotherapeutics. Yasunaga et al. developed an
antibody drug conjugate against type IV collagen that released the
antineoplastic drug SN-38 through the labile ester bond linker in the
tumor ECM [49]. Evaluation in mice with two types of subcutaneous
pancreatic tumors (stroma poor and stroma rich tumors) showed almost
complete tumor growth inhibition of stroma rich tumors treated with
the anti-collagen drug conjugate. Interestingly, growth of stroma poor
tumors was less aﬀected by the antibody-drug conjugate suggesting
speciﬁc targeting of stroma rich tumors. In spite of the abundant ex-
pression of collagen in the body, body weight was not aﬀected and no
toxicity in the liver, kidney and bone-marrow was observed, suggesting
that distribution to other organs may be limited. Liang et al. also tar-
geted collagen in the ECM of tumors. They designed an antibody drug
conjugate by combining a collagen (collagen type not speciﬁed) binding
domain peptide with the Fab fragment of a clinically approved antibody
(cetuximab) directed against the epidermal growth factor receptor
(EGFR) which has antitumor activity itself [50]. In a therapeutic in vivo
study with mice bearing subcutaneous EGFR positive tumors, tumor
growth was signiﬁcantly inhibited in mice treated with the collagen
binding domain-anti EGFR conjugate compared to cetuximab only. In
general, the full potential of tumoral ECM targeting was not utilized
because the therapeutic molecule required binding of a speciﬁc re-
ceptor (EGFR) on a tumor cell subset.
Next to collagen, galectin-1 has been used for targeting to the tu-
moral ECM. Galectin-1 is a carbohydrate binding protein that plays a
role in cellular interactions. Underlining the limitations of cellular
targeted therapies due to the tumor heterogeneity of triple negative
breast cancer (i.e. breast tumors not overexpressing the estrogen re-
ceptor, progesterone receptor and epidermal growth factor receptor-2),
Upreti and colleagues developed a tumor ECM targeting strategy di-
rected at galectin-1 [51,52]. Cisplatin and arsenic trioxide loaded li-
posomes functionalized with anginex, a small galectin-1 binding pep-
tide, were evaluated for their therapeutic eﬃcacy in an orthotopic
triple negative breast cancer mouse model. They showed signiﬁcant
tumor growth reduction compared to treatment with non-targeting
drug loaded liposomes. Although initial results were promising, an in-
creased eﬃcacy may be reached by applying extracellular release of the
Fig. 3. An example of an in vivo tumoral extracellular matrix targeting strategy. (A) Mice bearing A431 human epidermoid carcinoma xenografts showed strong tenascin-C expression
(green), especially around tumor vessels (red). (B) In tumors of mice treated with an antibody-drug conjugate directed against tenascin-C (green), the antibody was found to localize to
tenascin-C in the direct area of tumor vessels (red). (C) Tumors of mice injected with a control antibody (directed against hen egg lysozyme) did not show presence of the antibody. (D)
Results of an eﬃcacy study in mice with A431 human epidermoid carcinomas that were treated with tenascin-C targeting antibody-drug conjugate (closed circles) indicate a statistically
signiﬁcant tumor growth inhibition compared to control antibody-drug conjugate (against hen egg lysozyme; open circles) or vehicle only (PBS; triangles). Data points represent mean
tumor volume ± SEM, n= 5 per group. Blue: nuclei. Scale bars: 100 μm. Reprinted with permission [25]. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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cytotoxic agents instead of using liposomes requiring receptor mediated
endocytosis and release inside cells to be therapeutically active.
As proteoglycans are abundantly present in the ECM, they may be
used for targeting chemotherapeutics to the tumor ECM as well. For
instance, aggrecan, a proteoglycan expressed in the ECM of cartilage
but also abundantly present in the ECM of chondrosacromas was tar-
geted by Peyrode et al. [53–55]. Using a conjugate of quaternary am-
monium with the chemotherapeutic compound melphalan, aggrecan
was targeted in an orthotopic Swarm rat chondrosarcoma model. Re-
sults showed a reduction of tumor volume for the drug conjugate. The
reduction, however, was not signiﬁcantly diﬀerent from non-targeted
melphalan, although more toxicity was observed for this group in-
dicating an improved toxicity proﬁle for the aggrecan targeting drug
conjugate. Despite promising results, care should be taken with possible
oﬀ-targeting to aggrecan rich tissues such as cartilage, a tissue that was
not included in the toxicity evaluations, even though toxicity may be
limited due to the limited blood supply to cartilage. Another pro-
teoglycan targeted in the ECM of tumors is heparan sulfate, which is
found highly upregulated in ECM of tumors making it an attractive
target for tumoral ECM chemotherapeutic drug delivery [56]. Hu et al.
used a CGKRK peptide with high aﬃnity to heparan sulfate and con-
jugated it with an endothelial cell binding peptide to paclitaxel loaded
nanoparticles [57]. This strategy was evaluated in mice bearing in-
tracranial glioblastoma tumors and showed that mice treated with pa-
clitaxel loaded nanoparticles targeted against heparan sulfate and en-
dothelial cells signiﬁcantly improved survival. It is not clear whether
the eﬀect is through extracellular release with potential removal of
tumor supportive cells or by internalization in tumor cells only. Finally,
chondroitin sulfate can be a target in the tumoral ECM because of its
high expression in the ECM of various tumor types [58]. Lee et al. used
cisplatin loaded liposomes modiﬁed with the chondroitin sulfate
binding molecule TRX20 (3,5-dipentadecycloxybenzamidine hydro-
chloride) which showed tumor growth inhibition in a subcutaneous
mouse tumor model [59]. While the strategy was designed to target
chondroitin sulfate at tumor cell membranes, it may also be applied as
ECM targeting to tumors with chondroitin sulfate in the ECM. Our
group developed a drug delivery system that targets chondroitin sulfate
subtype-E (CS-E), which was found to be highly upregulated in the ECM
of ovarian cancer [60]. Although currently only evaluated in vitro,
doxorubicin loaded albumin particles functionalized with a scFv anti-
body against CS-E were indeed able to target CS-E and eﬃciently
eliminate ovarian cancer cells by extracellular drug release [20].
Overall, proteoglycans and glycosaminoglycans in the tumoral ECM
may oﬀer several opportunities, but care should be taken with oﬀ target
eﬀects to healthy tissue due to expression of these molecules
throughout the body.
4.3. Extracellular drug release
Next to the presence of promising targets in the ECM, a tumor ECM
drug delivery strategy is also highly dependent on the type of drug
carrier. Many chemotherapeutic drug delivery systems have been de-
veloped over the last decades. Each system has unique characteristics
that can be important for tumoral ECM drug delivery, such as size, drug
content, charge, base material, modiﬁcations, etc. An important char-
acteristic of drug delivery systems for tumoral ECM drug delivery is the
drug release mechanism. Upon release, most drug molecules will retain
in the tumor area because of the enhanced retention eﬀect and will pass
cell membranes due to the hydrophobic properties of the majority of
chemotherapeutics. However, if not rapidly taken up by tumor or tumor
supportive cells, there is a risk of diﬀusion back into the circulation,
which may result in oﬀ-target eﬀects. Unfortunately, preclinical studies
generally do not assess reuptake of released drugs into the circulation,
but such analyses should be included in future studies. Without suﬃ-
cient release of chemotherapeutics once a drug delivery system is
bound to its target, no therapeutic eﬀect will be induced. Therefore,
extracellular release once bound to the ECM of tumors is required. Next
to simple diﬀusion, with possible unwanted preliminary drug release,
several innovative release mechanisms have been developed. Examples
are triggered release by enzymes, pH, magnetism, heat, light, and ul-
trasound. For example, by exploiting the lower pH in the tumor ex-
tracellular matrix (6.2–6.9) caused by accumulation of lactic acid pro-
duced by highly proliferating tumor cells [61], Chiang et al. designed
tumor ECM targeting doxorubicin-loaded liposomes in which the imi-
dazole ring of histidine was protonated in an acetic environment re-
sulting in increased uptake of the doxorubicin liposomes [62]. Dong
et al. synthesized a pH and enzyme responsive doxorubicin delivery
system [63]. The acetic tumor environment exposed the gelatin-DNA-
doxorubicin complex to subsequently release doxorubicin by enzymatic
degradation of gelatin due to matrix metalloproteinases upregulated in
the tumoral ECM. In antibody-drug conjugates, triggered release is
applied as well. For example, Rossin et al. developed a non-inter-
nalizing antibody-drug conjugate with a click-to-release mechanism
[64]. Upon binding to the tumor speciﬁc membrane bound target, the
non-internalizing antibody-drug conjugate released its payload after
reaction of an administered activator compound. This strategy enables
release of the drug speciﬁcally at the tumor site as non-bound antibody-
drug complexes are allowed to be excreted from the body before ad-
ministration of the activator compound. Next to these examples, a
manifold of other release mechanisms have been developed. As thor-
ough discussion of these external/internal stimuli driven response is
beyond the scope of this review, we refer to excellent reviews on this
topic [61,65,66]. The combination of stimuli triggered release and
binding to a tumor ECM target seems a promising idea, but more studies
should be performed to indicate its full potential.
5. Future outlook
The therapeutic eﬀect of conventional tumor targeting chemother-
apeutic delivery systems that addresses molecules on cancer cells may
be limited by intratumoral heterogeneity and inadequate drug release
due to lysosomal entrapment. Combining the knowledge of tumor
heterogeneity and the importance of the tumor extracellular matrix
with its tumor supportive cells, delivery of chemotherapeutics to the
tumoral ECM may be a promising alternative. Various studies have
identiﬁed unique tumoral ECM targets. In vivo studies indicate that
targeting these unique tumoral ECM targets combined with extra-
cellular release of chemotherapeutics can improve treatment outcome.
Tumoral ECM targets should be critically selected. Potential expression
in healthy tissue may cause oﬀ-targeting with possibilities of inducing
toxicity and side eﬀects. Moreover, care should be taken when selecting
a drug delivery system. The eﬀect caused by extracellular drug release
and diﬀusion of the drug to tumor supportive cells in the tumor area
may be limited when the drug as such is not released extracellularly,
but instead is contained in a carrier that is taken up into the cell
through endocytosis. To overcome these limitations, stimuli driven
extracellular drug release may oﬀer promising opportunities. By ex-
ternal or internal triggered drug release, chemotherapeutic agents will
only be released in the tumor area and will be able to diﬀuse into tumor
cell and tumor supportive cells. Moreover, it may prevent early drug
release that results in exposure to healthy tissue. Next to chemother-
apeutic delivery, the emerging ﬁeld of immunotherapy may greatly
beneﬁt from tumor ECM drug delivery. In a study from Zegers et al.
[67], the chemokine IL2 was targeted to the tumoral ECM ﬁbronectin
extra domain B. Upon radiation, the cytotoxic eﬀect of inﬁltrating CD8
cytotoxic T lymphocytes was enhanced by the extracellular presence of
IL2, illustrating the possibilities to include tumor ECM targeted drug
delivery in immunotherapy.
Despite a number of promising in vivo results, no clinical studies
using tumor ECM targeted chemotherapeutic delivery were identiﬁed.
Therefore, to understand the full potential of this strategy, the step to
clinical studies should be taken once the most potential tumoral ECM
R. Raavé et al. Journal of Controlled Release 274 (2018) 1–8
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targeting strategy has been identiﬁed.
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